var data={"title":"Minocycline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Minocycline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6587?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=minocycline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Minocycline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=minocycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Minocycline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196900\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CoreMino;</li>\n      <li>Minocin;</li>\n      <li>Solodyn;</li>\n      <li>Ximino</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196940\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Tetracycline Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196905\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours (maximum: 400 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours; more frequent dosing intervals may be used (100 to 200 mg initially, followed by 50 mg 4 times daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne:</b> Oral: Capsule or immediate-release tablet: 50 to 100 mg twice daily. <b>Note:</b> The shortest possible duration should be used to minimize development of bacterial resistance; re-evaluate at 3 at 4 months (AAD [Zaenglein 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne (inflammatory, non-nodular, moderate to severe): </b> <b>Note:</b> Therapy should be continued for 12 weeks. Safety of use beyond 12 weeks has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsule (Ximino): Oral: 1 mg/kg (rounded to the nearest capsule) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release tablet: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Minolira:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">45 to 59 kg: 52.5 mg (one-half of the 105 mg tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">60 to 89 kg: 67.5 mg (one-half of the 135 mg tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">90 to 125 kg: 105 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">126 to 136 kg: 135 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CoreMino, Solodyn:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">45 to 49 kg: 45 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">50 to 59 kg: 55 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">60 to 71 kg: 65 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">72 to 84 kg: 80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">85 to 96 kg: 90 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">97 to 110 kg: 105 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">111 to 125 kg: 115 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">126 to 136 kg: 135 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cellulitis (purulent) due to community-acquired MRSA (off-label use):</b> Oral: Initial: 200 mg; Maintenance: 100 mg twice daily for 5 to 10 days (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chlamydial or </b> <b><i>Ureaplasma urealyticum </i></b> <b>infection, uncomplicated:</b> Oral, IV: Urethral, endocervical, or rectal: 100 mg every 12 hours for at least 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, uncomplicated (males):</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Without urethritis or anorectal infection:</i> Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours for at least 4 days (cultures 2 to 3 days post-therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Urethritis:</i> 100 mg every 12 hours for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leprosy (alternative agent) (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lepromatous (multibacillary): </i>100 mg once daily for 24 months in combination with clofazimine and rifampin (NHDP [HRSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tuberculoid (paucibacillary):</i> 100 mg once daily for 12 months in combination with rifampin (NHDP [HRSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal carrier state (manufacturer's labeling):</b> Oral: 100 mg every 12 hours for 5 days. <b>Note:</b> CDC recommendations do not mention use of minocycline for eradicating nasopharyngeal carriage of meningococcal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mycobacterium marinum:</i></b> Oral: 100 mg every 12 hours for 6 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nocardiosis (off-label use):</b> Oral: 100 to 200 mg every 12 hours, with or without other concomitant antimicrobials (Lerner 1996). Additional data may be necessary to further define the role of minocycline in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Staphylococci (oxacillin-sensitive or -resistant) oral phase treatment (after completion of pathogen-specific IV therapy) following 1-stage exchange:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total ankle, elbow, hip, or shoulder arthroplasty: 100 mg twice daily for 3 months; <b>Note:</b> Must be used in combination with rifampin (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total knee arthroplasty: 100 mg twice daily for 6 months; <b>Note:</b> Must be used in combination with rifampin (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic oral antimicrobial suppression (off-label use):</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cutibacterium</i> spp (alternative to penicillin or amoxicillin): 100 mg twice daily (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Staphylococci (oxacillin-resistant): 100 mg twice daily (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis (off-label use):</b> Oral: 100 mg twice daily (Kloppenburg 1994; O&rsquo;Dell 1997; O&rsquo;Dell 2001; Stone 2003; Tilley 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis:</b> Oral, IV: Initial: 200 mg for 1 dose; Maintenance: 100 mg every 12 hours for 10 to 15 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196925\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=minocycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Minocycline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Children &gt;8 years and Adolescents: Oral, IV: Initial: 4 mg/kg/dose for 1 dose; Maintenance: 2 mg/kg/dose every 12 hours (maximum: 400 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne (inflammatory, non-nodular, moderate to severe):</b> Children &ge;12 years and Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cellulitis (purulent) due to community-acquired MRSA (off-label use):</b> Oral: Children &gt;8 years: Initial: 4 mg/kg (maximum: 200 mg); Maintenance: 2 mg/kg/dose (maximum: 100 mg) every 12 hours for 5 to 10 days (Liu 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196906\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196907\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution. Consider decreasing dose or increasing dosing interval (extended release).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">CrCl &ge;80 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">CrCl &lt;80 mL/minute: Do not exceed 200 mg daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15035749\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, hepatotoxicity has been reported. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196875\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin: 50 mg, 75 mg [DSC], 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ximino: 90 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ximino: 135 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin: 50 mg [DSC], 100 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), disodium edta, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CoreMino: 45 mg, 90 mg, 135 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 55 mg [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 65 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 80 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 105 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 115 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 45 mg, 65 mg, 90 mg, 115 mg, 135 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196861\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28799613\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocin Kit contains minocycline oral capsules packaged with T3 Calming Wipes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocin for injection contains magnesium 2.2 mEq per vial</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29447371\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Minolira (minocycline extended release tablets): FDA approved May 2017; anticipated availability is currently unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196879\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 60 minutes; avoid rapid administration. The injectable route should be used only if the oral route is not feasible or adequate. Prolonged intravenous therapy may be associated with thrombophlebitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered with or without food. Administer with adequate fluid to decrease the risk of esophageal irritation and ulceration. Swallow pellet-filled capsule and extended-release tablet or capsule whole; do not chew, crush, or split. Minolira 105 mg and 135 mg extended-release tablets may be split on the score line.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196878\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute intestinal amebiasis:</b> Adjunctive therapy to amebicides in the treatment of acute intestinal amebiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral (immediate release) and IV:</i> Adjunctive therapy for the treatment of severe acne</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral (extended-release):</i> Treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and older</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinomycosis:</b> Treatment of actinomycosis caused by <i>Actinomyces israelii</i> when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax:</b> Treatment of anthrax caused by <i>Bacillus anthracis</i> when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asymptomatic carriers of</b>\n      <b>\n        <i> Neisseria meningitidis: </i></b> <i>Oral (immediate-release):</i> To eliminate the meningococci from the nasopharynx of asymptomatic carriers of <i>N. meningitidis</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Campylobacter:</b> Treatment of infections caused by <i>Campylobacter fetus</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera:</b> Treatment of cholera caused by <i>Vibrio cholerae</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Clostridium:</b> Treatment of infections caused by <i>Clostridium</i> spp when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gram-negative infections:</b> Treatment of infections caused by <i>Acinetobacter</i> spp, <i>Escherichia coli</i>, <i>Enterobacter aerogenes</i>, <i>Shigella</i> spp</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Listeriosis:</b> Treatment of listeriosis due to <i>Listeria monocytogenes</i> when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> Treatment of meningitis due to <i>Neisseria meningitidis</i> when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic infections:</b> Treatment of inclusion conjunctivitis or trachoma caused by <i>Chlamydia trachomatis</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Relapsing fever:</b> Treatment of relapsing fever caused by <i>Borrelia recurrentis</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections:</b> Treatment of respiratory tract infections caused by <i>Haemophilus influenzae</i>, <i>Klebsiella</i> spp, or <i>Mycoplasma pneumonia</i>. For the treatment of upper respiratory tract infections caused by <i>Streptococcus pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rickettsial infections:</b> Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by <i>Rickettsiae</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sexually transmitted infections:</b> Treatment of lymphogranuloma venereum caused by <i>C. trachomatis</i>; nongonococcal urethritis, endocervical, or rectal infections in adults caused by <i>Ureaplasma urealyticum</i> or <i>C. trachomatis</i>; donovanosis (granuloma inguinale) caused by <i>Klebsiella granulomatis</i>; syphilis caused by <i>Treponema pallidum</i> subspecies <i>pallidum</i>, when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections caused by <i>Staphylococcus aureus</i> (not considered a first-line agent for any staphylococcal infection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections:</b> Treatment of urinary tract infections caused by <i>Klebsiella</i> species</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vincent infection:</b> Treatment of Vincent infection caused by <i>Fusobacterium fusiforme</i> when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Yaws:</b> Treatment of yaws caused by <i>T. pallidum</i> subspecies <i>pertenue</i> when penicillin is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Zoonotic infections:</b> Treatment of psittacosis (ornithosis) due to <i>Chlamydia psittaci</i>; plague due to <i>Yersinia pestis</i>; tularemia due to <i>Francisella tularensis</i>; brucellosis due to <i>Brucella</i> spp (in conjunction with streptomycin); bartonellosis due to <i>Bartonella bacilliformis</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469238\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cellulitis (purulent) due to community-acquired MRSA; Leprosy; Nocardiosis; Prosthetic Joint Infection; Rheumatoid arthritis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196948\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dynacin may be confused with Dyazide, Dynapen </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin may be confused with Indocin, Lincocin, Minizide, niacin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196868\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (9%), fatigue (9%), malaise (4%), drowsiness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (5%), urticaria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure (reversible), anaphylaxis, angioedema, autoimmune hepatitis, balanitis, bulging fontanel, <i>Clostridium difficile-</i>associated diarrhea, DRESS syndrome, dysphagia, enterocolitis, eosinophilia, erythema multiforme, exacerbation of systemic lupus erythematosus, exfoliative dermatitis, fixed drug eruption, glossitis, hearing loss, hemolytic anemia, hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hypersensitivity reaction, IgA vasculitis, lupus-like syndrome, malignant neoplasm of thyroid, microscopic thyroid discoloration (brown-black), mucous membrane pigmentation, myocarditis, pancreatitis, pericarditis, pneumonitis, polyarthralgia, pseudomembranous colitis, pseudotumor cerebri, pulmonary infiltrates (with eosinophilia), serum sickness, skin photosensitivity, skin pigmentation, Stevens-Johnson syndrome, thrombocytopenia, thyroid dysfunction, tooth discoloration, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196882\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to minocycline, other tetracyclines, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe liver disease; complete renal failure; myasthenia gravis; use in children &lt;13 years of age; pregnancy; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196865\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune syndromes: Lupus-like, hepatitis, and vasculitis autoimmune syndromes (including serum sickness [eg fever, arthralgia, and malaise]) have been reported; discontinue if symptoms occur and assess liver function tests, ANA, and CBC.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benign intracranial hypertension (eg, pseudotumor cerebri [PTC]): Benign intracranial hypertension (headache, blurred vision, diplopia, vision loss, and/or papilledema) has been associated with use. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Concomitant use of isotretinoin (known to cause PTC) and minocycline should be avoided. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patients until they stabilize.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Lightheadedness, dizziness, and vertigo may occur; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Symptoms usually disappear with continued therapy and when the drug is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Serious liver injury, including irreversible drug induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with use for acne treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperpigmentation: Hyperpigmentation may occur in nails, bone, skin (including scar and injury sites), eyes, sclerae, thyroid, oral cavity, visceral tissue, and heart valves; skin and oral hyperpigmentation are independent of dose or administration duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis has been reported; discontinue drug immediately and institute supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; use caution in patients with renal impairment as this may lead to azotemia, hyperphosphatemia, acidosis, and possibly to drug accumulation and potential hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; avoid use of use tanning equipment or UVA/B treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin rash: Rash, erythema multiforme, Stevens Johnson syndrome or eosinophilia, fever, and organ failure (Drug Rash with Eosinophilia and Systemic Symptoms [DRESS] syndrome), may occur; onset of symptoms may be delayed up to several weeks; fatal in up to 10% of cases; discontinue treatment immediately if DRESS syndrome is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Hepatotoxicity has been reported; use with caution in patients with hepatic impairment or in conjunction with other hepatotoxic drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;80 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May cause tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration; more common with long-term use, but observed with repeated, short courses; use of tetracyclines should be avoided during tooth development (infancy and children &le;8 years of age) unless other drugs are not likely to be effective or are contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Do not use during pregnancy. In addition to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Magnesium content: Parenteral (IV) formulation contains magnesium; monitor serum magnesium in patients with renal impairment and signs of magnesium intoxication (eg, flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression leading to respiratory paralysis). Also use with caution and closely monitor patients with heart block or myocardial damage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Acne: The American Academy of Dermatology acne guidelines recommends minocycline be used as adjunctive treatment for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Concomitant topical therapy with benzoyl peroxide or a retinoid is recommended should be administered with systemic antibiotic therapy (eg, minocycline) and continued for maintenance after the antibiotic course is completed (AAD [Zaenglein 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299717\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196870\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9653&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Minocycline may decrease the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Minocycline may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Tetracyclines may decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Minocycline may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Tetracyclines. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 h before sucroferric oxyhydroxide.  Specific dose separation guidelines for other tetracyclines are not presently available.  No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the absorption of Tetracyclines. Only a concern when both products are administered orally. Management: Consider doxycycline as a noninteracting tetracycline derivative. Separate dose administration of oral tetracycline derivative and oral zinc salts by at least 2 hours to minimize interaction.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196895\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Minocycline serum concentrations are not significantly altered if taken with food or dairy products. Management: Administer without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196872\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196885\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Minocycline crosses the placenta. Tetracycline-class antibiotics may cause fetal harm following maternal use in pregnancy. Rare spontaneous reports of congenital anomalies, including limb reduction, have been reported following maternal minocycline use. Due to limited information, a causal association cannot be established. Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas 2011). Minocycline is not recommended for the treatment of Rocky Mountain Spotted Fever (Biggs 2016), Q fever (Anderson 2013), or anthrax infection (Meaney-Delman 2014) in pregnant women. When systemic antibiotics are needed for dermatologic conditions in pregnant women, other agents are preferred (Kong 2013; Murase 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196886\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline is present in breast milk (Brogden 1975).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Oral absorption is not affected by dairy products; therefore, oral absorption of minocycline by the breastfed infant would not be expected to be diminished by the calcium in the maternal milk. There have been case reports of black discoloration of breast milk in women taking minocycline (Basler 1985; Hunt 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As a class, tetracyclines have generally been avoided in breastfeeding women due to theoretical concerns that they may permanently stain the teeth of the breastfeeding infant (Chung 2002). Some sources note that breastfeeding can continue during tetracycline therapy (Chung 2002; WHO 2002) but recommend use of alternative medications when possible (WHO 2002). Other sources note that short-term exposure may be acceptable; however, long-term use of tetracyclines (eg, for the treatment of acne) should be avoided in breastfeeding women (Pugashetti 2013). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (Chung 2002; WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934391\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">LFTs, BUN, renal function with long-term treatment, serum magnesium in patients with renal impairment; if symptomatic for autoimmune disorder, include ANA, CBC; ophthalmologic evaluation if visual disturbances occur. If used for syphilis, obtain follow up serologic tests 3 months after treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196864\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; cell wall synthesis is not affected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196881\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed to most body fluids, bile, and tissues; poor CNS penetration; deposits in fat for extended periods; V<sub>d</sub>: 0.14 to 0.7 L/kg (Zhanel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 55% to 96% (Zhanel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 90% to 100% (Zhanel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 15 to 23 hours; 11 to 16 hours (hepatic impairment); 18 to 69 hours (renal impairment); Oral: 16 hours (range: 11 to 17 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Capsule, pellet filled: 1 to 4 hours; Tablet: 1 to 3 hours; Extended release tablet: 3.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (5% to 12% excreted unchanged) (Brogden 1975; Zhanel 2004); feces (20% to 34%) (Brogden 1975)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196884\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Ximino Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $839.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (30): $839.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Minocin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $360.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $2,940.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Minocycline HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $169.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $197.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $169.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Minocin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $185.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (CoreMino Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (30): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (30): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Minocycline HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (30): $605.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg (30): $1,306.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $605.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">115 mg (30): $1,306.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (30): $605.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Solodyn Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">55 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">105 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">115 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Minocycline HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $343.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $504.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $300.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196888\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acneclin (AR, EC);</li>\n      <li>Akamin (AU);</li>\n      <li>Antinocil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bagomicina (CL, EC);</li>\n      <li>Borymycin (MY, SG, TW);</li>\n      <li>Cyclimycin (ZA);</li>\n      <li>Cynomycin (IN);</li>\n      <li>Delnil (CL);</li>\n      <li>Dentomycin (IE);</li>\n      <li>Haicin (PH);</li>\n      <li>Klinomycin (LU);</li>\n      <li>Lederderm (DE);</li>\n      <li>Melicin (TW);</li>\n      <li>Mestacine (FR);</li>\n      <li>Micromycin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Minaxen (MT, TR);</li>\n      <li>Mino-50 (LU);</li>\n      <li>Minocin (AE, BB, BE, BH, BO, BR, CH, CN, EC, EG, ES, GB, GR, HK, ID, IE, IT, KR, KW, LU, MX, NL, PE, PH, PK, PR, PT, PY, QA, SA, UY, VE, VN);</li>\n      <li>Minocin Akne (SI);</li>\n      <li>Minocin MR (MT);</li>\n      <li>Minoclin (IL);</li>\n      <li>Minocyclin (CZ);</li>\n      <li>Minocyclin 50 Stada (DE);</li>\n      <li>Minogran (CO);</li>\n      <li>Minolin (LK);</li>\n      <li>Minoline (TW);</li>\n      <li>Minolox (VN);</li>\n      <li>Minomycin (AU, NZ);</li>\n      <li>Minosil (IE);</li>\n      <li>Minostad (AT);</li>\n      <li>Minot (CO, CR, DO, EC, GT, HN, NI, PA, PE, SV);</li>\n      <li>Minotab (LU);</li>\n      <li>Minotab 50 (BE, NZ, ZA);</li>\n      <li>Minox (IE);</li>\n      <li>Minoz MR (RO);</li>\n      <li>Mirosin (TW);</li>\n      <li>Mynocine (FR);</li>\n      <li>Parocline (FR);</li>\n      <li>Periocline (JP);</li>\n      <li>Ximino (BM)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23109210\"></a>Anderson M, Kuzniar TJ, et al. Pulmonary nocardiosis in a patients with chronic obstructive pulmonary disease- case report and literature review. <i>Pneumonol Alergol Pol</i>. 2012;80(6):565-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/23109210/pubmed\" target=\"_blank\" id=\"23109210\">23109210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apo-minocycline [product monograph]. Toronto, Ontario, Canada: Apotex Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basler RS and Lynch PJ, &quot;Black Galactorrhea as a Consequence of Minocycline and Phenothiazine Therapy,&quot; <i>Arch Dermatol</i>, 1985, 121(3):417-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/4038862/pubmed\" target=\"_blank\" id=\"4038862\">4038862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogden RN, Speight TM, and Avery GS, &quot;Minocycline: A Review of Its Antibacterial and Pharmacokinetic Properties and Therapeutic Use,&quot; <i>Drugs</i>, 1975, 9(4):251-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/1173232/pubmed\" target=\"_blank\" id=\"1173232\">1173232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, and Blumer JL, &quot;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&quot; <i>Paediatr Drugs</i>, 2002, 4(12):817-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/12431134/pubmed\" target=\"_blank\" id=\"12431134\">12431134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CoreMino (minocycline hydrochloride) extended-release tablets [prescribing information]. Malvern, PA: Encore Dermatology; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21155087\"></a>Dodiuk-Gad R, Cohen E, Ziv, M, et al. Cutaneous nocardiosis: report of two cases and review of the literature. <i>Int J Derm</i>. 2010; 49(12):1380-1385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/21155087/pubmed\" target=\"_blank\" id=\"21155087\">21155087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghislain PD and Roujeau JC, &quot;Treatment of Severe Drug Reactions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Hypersensitivity Syndrome,&quot; Dermatol Online J, 2002, 8(1):5. Available at http://dermatology.cdlib.org/DOJvol8num1/reviews/drugrxn/ghislain.html12165215</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goulden V, &ldquo;Guidelines for the Management of Acne Vulgaris in Adolescents,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(5):301-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/12716217/pubmed\" target=\"_blank\" id=\"12716217\">12716217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: recommended treatment regimens. Available at <a href=\"https://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html\" target=\"_blank\">https://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html</a>. Accessed March 31, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt MJ, Salisbury EL, Grace J, et al, &quot;Black Breast Milk Due to Minocycline Therapy,&quot; <i>Br J Dermatol</i>, 1996, 134(5):943-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/8736342/pubmed\" target=\"_blank\" id=\"8736342\">8736342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. <i>Arthritis Rheum</i>. 1994;37(5):629-636.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/8185689/pubmed\" target=\"_blank\" id=\"8185689\">8185689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/23657872/pubmed\" target=\"_blank\" id=\"23657872\">23657872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8783685\"></a>Lerner PI. Nocardiosis. <i>CID</i>. 1996;22(6):891-905.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/8783685/pubmed\" target=\"_blank\" id=\"8783685\">8783685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus Aureus</i> Infections in Adults and Children: Executive Summary,&rdquo; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minocin (minocycline injection) [prescribing information]. Parsippany, NJ: The Medicines Company; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minocin (minocycline pellet-filled capsules) [prescribing information]. Bridgewater, TX: Valeant Pharmaceuticals; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minocycline hydrochloride [prescribing information]. Basking Ridge, NJ: Torrent Pharma; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minolira (minocycline) extended-released tablets [prescribing information]. Princeton, NJ: Promius Pharma LLC; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):e1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mylonas I, &quot;Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration,&quot; <i>Arch Gynecol Obstet</i>, 2011, 283(1):7-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/20814687/pubmed\" target=\"_blank\" id=\"20814687\">20814687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheum</i>. 1997;40(5):842-848.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/9153544/pubmed\" target=\"_blank\" id=\"9153544\">9153544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. <i>Arthritis Rheum</i>. 2001;44(10):2235-2241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/11665963/pubmed\" target=\"_blank\" id=\"11665963\">11665963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6345836\"></a>Petersen EA, Nash ML, Mammana RB, Copeland JG. Minocycline treatment of pulmonary nocardiosis. <i>JAMA</i>.1983:250(7):930-932.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/6345836/pubmed\" target=\"_blank\" id=\"6345836\">6345836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant patients. <i>Dermatol Ther</i>. 2013;26(4):302-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/23914887/pubmed\" target=\"_blank\" id=\"23914887\">23914887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo; <i>Mayo Clin Proc</i>, 1991, 66(12):1270-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/1749296/pubmed\" target=\"_blank\" id=\"1749296\">1749296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solodyn (minocycline) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; September 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/1749296/pubmed\" target=\"_blank\" id=\"1749296\">1749296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strauss JS, Krowchuk DP, Leyden JJ, et al, &ldquo;Guidelines of Care for Acne Vulgaris Management,&rdquo; <i>J Am Acad Dermatol</i>, 2007, 56(4):651-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/17276540/pubmed\" target=\"_blank\" id=\"17276540\">17276540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. <i>J Rheumatol</i>. 2003;30(10):2112-2122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/14528503/pubmed\" target=\"_blank\" id=\"14528503\">14528503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Threlkeld.1997\"></a>Threlkeld SC, Hooper DC. Update on Management of Patients with <i>Nocardia</i> Infection. Current Clinical Topics in Infectious Diseases. Remington JS, Swartz MN, eds. Malden: Blackwell Science, 1997. 1-23.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tilley BC, Alarc&oacute;n GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. <i>Ann Intern Med</i>. 1995;122(2):81-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/7993000/pubmed\" target=\"_blank\" id=\"7993000\">7993000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs&rdquo;. 2002. Available at: www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ximino (minocycline) [prescribing information]. Jacksonville, FL: Ranbaxy Labs; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed May 17, 2016.26897386</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhanel GG, Homenuik K, Nichol K, et al, &quot;The Glycylcyclines: A Comparative Review With the Tetracyclines,&quot; <i>Drugs</i>, 2004, 64(1):63-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-drug-information/abstract-text/14723559/pubmed\" target=\"_blank\" id=\"14723559\">14723559</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9653 Version 249.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F196900\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196940\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F196905\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F196925\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F196906\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F196907\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15035749\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196875\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F196861\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28799613\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F29447371\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F196879\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F196878\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469238\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F196948\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196868\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196882\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196865\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299717\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F196870\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F196895\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196872\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196885\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F196886\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2934391\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196864\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F196881\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F196884\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F196888\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9653|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=minocycline-patient-drug-information\" class=\"drug drug_patient\">Minocycline: Patient drug information</a></li><li><a href=\"topic.htm?path=minocycline-pediatric-drug-information\" class=\"drug drug_pediatric\">Minocycline: Pediatric drug information</a></li></ul></div></div>","javascript":null}